Clinical Trials Logo

Leukemia, Lymphoid clinical trials

View clinical trials related to Leukemia, Lymphoid.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT04943952 Approved for marketing - Clinical trials for Acute Lymphoblastic Leukemia

JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase

Start date: n/a
Phase:
Study type: Expanded Access

This study is an Expanded Access Protocol (EAP) of JZP458 in participants with ALL/LBL who are hypersensitive to an E.coli-derived asparaginase (allergic reaction or silent inactivation) and unable to access alternative licensed treatment, to receive JZP458 treatment prior to potential Food and Drug Administration (FDA) approval and commercial availability.

NCT ID: NCT02437019 Approved for marketing - Clinical trials for B-cell Chronic Lymphocytic Leukemia

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to provide early access to Ibrutinib treatment for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and collect additional safety data while the medication is not commercially available.

NCT ID: NCT02136511 Approved for marketing - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Start date: n/a
Phase: N/A
Study type: Expanded Access

This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible for other Gilead-sponsored studies.

NCT ID: NCT01868893 Approved for marketing - Clinical trials for Chronic Lymphocytic Leukemia

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Start date: August 2013
Phase: Phase 4
Study type: Expanded Access

This is a multicenter, open-label, single-arm, expanded access treatment study designed to provide obinutuzumab to patients with previously untreated CLL in combination with chlorambucil and to evaluate the safety and efficacy of obinutuzumab administered in combination with chlorambucil. This study will enroll patients with previously untreated CD20-positive CLL requiring treatment according to the IWCLL guidelines (Hallek et al 2008), as assessed by the investigator.

NCT ID: NCT01592136 Approved for marketing - Clinical trials for Chronic Myeloid Leukemia (CML)

Expanded Access Program of Ponatinib

Start date: n/a
Phase: N/A
Study type: Expanded Access

This protocol will allow expanded access of ponatinib to patients ≥18 years with chronic myeloid leukemia (CML) any phase or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) who have failed all available treatment options.